Re-Defining Frailty and Improving Outcomes Through Prehabilitation in Patients With Pancreatic, Liver, or Gastric Cancer, The RIOT Trial

Sponsor
Ohio State University Comprehensive Cancer Center (Other)
Overall Status
Recruiting
CT.gov ID
NCT04602026
Collaborator
National Cancer Institute (NCI) (NIH)
50
1
3
51.5
1

Study Details

Study Description

Brief Summary

This trial studies how well a prehabilitation program works to improve patient outcomes after surgery compared to the normal standard of care prehabilitation in frail patients undergoing surgery for pancreatic, liver, or gastric cancer. Frailty is defined as the pathophysiology of aging or through the accumulation of physiologic and functional deficits. Prehabilitation programs seek to optimize the medical and physical state of patients prior to undergoing surgery with the goal of improving outcomes following surgery. Despite evidence for its importance in health outcomes for frail patients, prehabilitation programs have not been well studied in cancer surgery populations. This trial may provide researchers with more information on how to improve patient outcomes after cancer surgery through the use of prehabilitation programs.

Condition or Disease Intervention/Treatment Phase
  • Other: Best Practice
  • Behavioral: Exercise Intervention
  • Procedure: Physical Therapy
  • Other: Questionnaire Administration
N/A

Detailed Description

PRIMARY OBJECTIVES:
  1. To develop a novel, multi-dimensional index of physiologic reserve and resilience specific to surgical cancer patients.

  2. To implement and assess a novel comprehensive multidimensional prehabilitation program on frail cancer surgery patients.

OUTLINE: Non-frail patients are assigned to Arm 1. Frail patients are randomized to Arms 2 or 3.

ARM I: Non-frail patients receive standard of care.

ARM II: Frail patients receive standard of care.

ARM III: Frail patients undergo a physical therapy consultation and complete home exercises 3 days per week.

After completion of study treatment, patients are followed up at 2 weeks after surgery and then every 3 months.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Supportive Care
Official Title:
Re-Defining Frailty and Improving Outcomes Through Prehabilitation (RIOT Trial)
Actual Study Start Date :
Sep 14, 2020
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Arm I (best practice)

Non-frail patients receive standard of care.

Other: Best Practice
Receive standard of care
Other Names:
  • standard of care
  • standard therapy
  • Other: Questionnaire Administration
    Ancillary studies

    Active Comparator: Arm II (best practice)

    Frail patients receive standard of care.

    Other: Best Practice
    Receive standard of care
    Other Names:
  • standard of care
  • standard therapy
  • Other: Questionnaire Administration
    Ancillary studies

    Experimental: Arm III (physical therapy consultation, exercise intervention)

    Frail patients undergo a physical therapy consultation and complete home exercises 3 days per week.

    Behavioral: Exercise Intervention
    Complete home exercise intervention

    Procedure: Physical Therapy
    Undergo physical therapy
    Other Names:
  • Physiatric Procedure
  • Physical Medicine Procedure
  • Physical Therapeutics
  • Physical Therapy Procedure
  • Physiotherapy
  • Physiotherapy Procedure
  • PT
  • Other: Questionnaire Administration
    Ancillary studies

    Outcome Measures

    Primary Outcome Measures

    1. Frailty assessment [Baseline]

      A rapid assessment for frailty using the widely used 5-item fatigue, resistance, ambulation, illness, & loss of weight (FRAIL) questionnaire will be performed. Patients are identified as frail by scoring 2 or more points on the FRAIL questionnaire. The frailty assessment will be aimed at identifying factors related to the 6 characteristics of frailty: physical performance, gait speed, mobility, nutritional status, mental health and cognition.

    2. Morbidity [Baseline]

      Will be assessed using standardized case report forms.

    3. Complication burden [Baseline]

      Will be calculated using the Comprehensive Complication Index (CCI). This method is more powerful than standard binary measures of morbidity (presence/absence of individual events) as it presents a quantitative score based on an aggregate weighted total ranging from 0 (no complications) to 100 (death).

    4. Health-related quality of life (composite measure) [Baseline, 2 weeks, 3, 6, 12 months]

      Will be recorded by administration of the Patient Reported Outcomes Measurement Information System (PROMIS) health-related quality of life questionnaire. PROMIS is a validated set of patient-centered measures that evaluates and monitors life domains (physical, mental, social health) and provide standardized patient reported outcome resources for use in clinical research and practice.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Scheduled for pancreatic, liver or gastric cancer surgery
    Exclusion Criteria:
    • Non-English speaking

    • Prisoners

    • Persons unable to provide informed consent

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Ohio State University Comprehensive Cancer Center Columbus Ohio United States 43210

    Sponsors and Collaborators

    • Ohio State University Comprehensive Cancer Center
    • National Cancer Institute (NCI)

    Investigators

    • Principal Investigator: Aslam Ejaz, MD, MPH, Ohio State University Comprehensive Cancer Center

    Study Documents (Full-Text)

    None provided.

    More Information

    Additional Information:

    Publications

    None provided.
    Responsible Party:
    Aslam Ejaz, Principal Investigator, Ohio State University Comprehensive Cancer Center
    ClinicalTrials.gov Identifier:
    NCT04602026
    Other Study ID Numbers:
    • OSU-20057
    • NCI-2020-04925
    • P30CA016058
    First Posted:
    Oct 26, 2020
    Last Update Posted:
    Oct 27, 2020
    Last Verified:
    Oct 1, 2020
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 27, 2020